- Home
- SAIA vs QGEN Comparison
SAIA vs QGEN Comparison
Compare SAIA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAIA | QGEN |
|---|---|---|
| Founded | 1924 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.2B |
| IPO Year | 2002 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SAIA | QGEN |
|---|---|---|
| Price | $445.87 | $34.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $391.06 | $45.76 |
| AVG Volume (30 Days) | 467.2K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $3,234,286,000.00 | N/A |
| Revenue This Year | $7.29 | $8.18 |
| Revenue Next Year | $9.08 | $5.71 |
| P/E Ratio | $47.11 | ★ $24.01 |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $248.37 | $33.17 |
| 52 Week High | $454.88 | $57.82 |
Technical Indicators
Market Signals| Indicator | SAIA | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 25.38 |
| Support Level | $324.03 | N/A |
| Resistance Level | N/A | $49.16 |
| Average True Range (ATR) | 18.68 | 0.95 |
| MACD | 0.31 | -0.58 |
| Stochastic Oscillator | 77.68 | 10.37 |
Price Performance
Historical ComparisonAbout SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).